QL1A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strategic Lex Acquisition Expands Molecular POCThe Lex acquisition adds an ultrafast molecular point-of-care instrument and initial orders with expected instrument placements in 2026 and assay pull-through revenue starting 2027. This materially broadens the instrument-installed base and creates a durable recurring consumables revenue stream once ramped.
Diversified Non-respiratory Revenue MixMore than half of revenue is non-respiratory (labs and transfusion products), reducing dependence on seasonal respiratory demand. A broader labs and immunohematology base supports steadier consumable pull-through and makes underlying revenue less cyclical over the medium term.
Clear Margin And Free Cash Flow Targets Plus Cost ActionsManagement has articulated a concrete plan—cost actions, working capital gains and product launches—targeting a sustainable ~23% adjusted EBITDA margin and positive FCF. If executed, these initiatives can structurally improve operating leverage and restore self-funding capacity over the next 2–6 months.
Bears Say
Deteriorated Profitability And Net LossesThe swing to sizable net losses and negative operating earnings reflects structural margin pressure below gross profit and weaker revenue trends. Persistent loss-making reduces retained earnings and limits flexibility for reinvestment or cushioning future shocks until profitability stabilizes.
Weakened Cash Generation; Negative Free Cash FlowOperating cash flow deterioration and continued negative free cash flow materially constrain internal funding for R&D, capex, and working capital. Over 2–6 months, this increases dependence on external financing and reduces the firm's resilience to execute strategic investments or absorb further revenue volatility.
China Distributor Pause And Ongoing Respiratory Demand RiskDistributor pauses tied to draft national IVD pricing and a materially weaker respiratory season create structural uncertainty in a key market and product category. Policy-driven pricing changes and demand pauses can reduce volumes and margin durability into 2027, complicating recovery and planning.
QuidelOrtho News
QL1A FAQ
What was Quidelortho Corporation’s price range in the past 12 months?
Currently, no data Available
What is Quidelortho Corporation’s market cap?
Quidelortho Corporation’s market cap is CHF1.00B.
When is Quidelortho Corporation’s upcoming earnings report date?
Quidelortho Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Quidelortho Corporation’s earnings last quarter?
Quidelortho Corporation released its earnings results on May 05, 2026. The company reported -$0.032 earnings per share for the quarter, missing the consensus estimate of $0.289 by -$0.321.
Is Quidelortho Corporation overvalued?
According to Wall Street analysts Quidelortho Corporation’s price is currently Undervalued.
Does Quidelortho Corporation pay dividends?
Quidelortho Corporation does not currently pay dividends.
What is Quidelortho Corporation’s EPS estimate?
Quidelortho Corporation’s EPS estimate is -0.02.
How many shares outstanding does Quidelortho Corporation have?
Currently, no data Available
What happened to Quidelortho Corporation’s price movement after its last earnings report?
Quidelortho Corporation reported an EPS of -$0.032 in its last earnings report, missing expectations of $0.289. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Quidelortho Corporation?
Currently, no hedge funds are holding shares in CH:QL1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF10.01 (― Downside)
CHF10.01 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.22%
12-Months-Change
Fundamentals
Return on Equity
-56.31%
Trailing 12-Months
Asset Growth
-12.89%
Trailing 12-Months
Company Description
Quidelortho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QL1A Company Deck
QL1A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: near-term headwinds were significant (a ~30% weaker respiratory season, an 8% decline in labs revenue, quarter-level margin and cash flow pressure, and China distributor pauses), but management emphasized strategic progress—completion of the Lex acquisition, new product launches (troponin, VITROS 450), cost actions, and a full-year plan targeting a 23% adjusted EBITDA margin and positive free cash flow of $100M–$120M. Given the company’s proactive mitigation steps, clear product and pipeline catalysts, and multi-pronged margin initiatives versus the material but largely contextual short-term revenue and cash setbacks, the tone is balanced between caution on near-term execution risks and optimism on medium-term recovery and margin improvement.View all CH:QL1A earnings summariesQL1A Stock 12 Month Forecast
Average Price Target
$10.01
Options Prices
Currently, No data available
---